Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V Alessi, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Lingzhi Hong, Jianjun Zhang, John V Heymach, Don L Gibbons, Andrew J Plodkowski, Vignesh Ravichandran, Mark T A Donoghue, Chad Vanderbilt, Marc Ladanyi, Charles M Rudin, Mark G Kris, Gregory J Riely, Jamie E Chaft, Matthew D Hellmann, Natalie I Vokes, Mark M Awad, Adam J Schoenfeld
PURPOSE: We sought to identify features of patients with advanced non-small cell lung cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors (ICIs), and how these might differ from features predictive of short-term response (STR). EXPERIMENTAL DESIGN: We performed a multicenter retrospective analysis of patients with advanced NSCLC treated with ICIs over ten years. LTR and STR were defined as response ≥ 24 months and response < 12 months, respectively...
July 11, 2023: Clinical Cancer Research
#22
JOURNAL ARTICLE
Jonathan A Ledesma, Jesse C Ottaway, Mark J Lambrechts, Azra Dees, Terence L Thomas, Mark F Kurd, Kris E Radcliff, David G Anderson
OBJECTIVE: To compare the early radiographic and clinical outcomes of expandable uniplanar versus biplanar interbody cages used for single-level minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). METHODS: A retrospective review of 1-level MIS-TLIFs performed with uniplanar and biplanar polyetheretherketone cages was performed. Radiographic measurements were performed on radiographs taken preoperatively, at 6-week follow-up, and 1-year follow-up...
June 2023: Neurospine
#23
JOURNAL ARTICLE
Mark Paul Selda Rivarez, Chantal Faure, Laurence Svanella-Dumas, Anja Pecman, Magda Tušek Žnidarič, Deborah Schönegger, Kris De Jonghe, Arnaud G Blouin, David Rasmussen, Sébastien Massart, Maja Ravnikar, Denis Kutnjak, Armelle Marais, Thierry Candresse
High-throughput sequencing (HTS) and sequence mining tools revolutionized virus detection and discovery in recent years and implementing them with classical plant virology techniques results to a powerful approach to characterize viruses. An example of a virus discovered through HTS is Solanum nigrum ilarvirus 1 (SnIV1) ( Bromoviridae ), which was recently reported in various solanaceous plants from France, Slovenia, Greece, and South Africa. It was likewise detected in grapevines (Vitaceae) and several Fabaceae and Rosaceae plant species...
July 3, 2023: Phytopathology
#24
RANDOMIZED CONTROLLED TRIAL
Gideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, Kris V Kowdley, John M Vierling, Cynthia Levy, Andreas E Kremer, Ehud Zigmond, Pietro Andreone, Stuart C Gordon, Christopher L Bowlus, Eric J Lawitz, Richard J Aspinall, Daniel S Pratt, Karina Raikhelson, Maria S Gonzalez-Huezo, Michael A Heneghan, Sook-Hyang Jeong, Alma L Ladrón de Guevara, Marlyn J Mayo, George N Dalekos, Joost P H Drenth, Ewa Janczewska, Barbara A Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J Trivedi, Lisa Forman, David E J Jones, Stephen D Ryder, Mark G Swain, Alexandra Steinberg, Pol F Boudes, Yun-Jung Choi, Charles A McWherter
BACKGROUND AND AIMS: ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA). APPROACH AND RESULTS: Patients were randomized 1:1:1 to oral seladelpar 5 mg (n=89), 10 mg (n=89), placebo (n=87) daily (with UDCA, as appropriate)...
August 1, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#25
JOURNAL ARTICLE
Monica F Chen, Soo-Ryum Yang, Jinru Shia, Jeffrey Girshman, Sippy Punn, Clare Wilhelm, Mark G Kris, Emiliano Cocco, Alexander Drilon, Nitya Raj
No abstract text is available yet for this article.
May 2023: JCO Precision Oncology
#26
REVIEW
Mark G Kris, Tetsuya Mitsudomi, Solange Peters
Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26-45%; stage II: 42-62%; stage III: 70-77%). For patients with metastatic lung cancer and tumours that harbour epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKIs) have improved survival. Their effectiveness in advanced stages of NSCLC raises the possibility that these agents may improve outcomes for patients with resectable EGFR-mutated lung cancer...
April 28, 2023: Translational Lung Cancer Research
#27
JOURNAL ARTICLE
Solène Derville, Leigh G Torres, Seth D Newsome, Christopher J Somes, Luciano O Valenzuela, Hannah B Vander Zanden, C Scott Baker, Martine Bérubé, Geraldine Busquets-Vass, Kris Carlyon, Simon J Childerhouse, Rochelle Constantine, Glenn Dunshea, Paulo A C Flores, Simon D Goldsworthy, Brittany Graham, Karina Groch, Darren R Gröcke, Robert Harcourt, Mark A Hindell, Pavel Hulva, Jennifer A Jackson, Amy S Kennedy, David Lundquist, Alice I Mackay, Petra Neveceralova, Larissa Oliveira, Paulo H Ott, Per J Palsbøll, Nathalie J Patenaude, Victoria Rowntree, Mariano Sironi, Els Vermeuelen, Mandy Watson, Alexandre N Zerbini, Emma L Carroll
Assessing environmental changes in Southern Ocean ecosystems is difficult due to its remoteness and data sparsity. Monitoring marine predators that respond rapidly to environmental variation may enable us to track anthropogenic effects on ecosystems. Yet, many long-term datasets of marine predators are incomplete because they are spatially constrained and/or track ecosystems already modified by industrial fishing and whaling in the latter half of the 20th century. Here, we assess the contemporary offshore distribution of a wide-ranging marine predator, the southern right whale (SRW, Eubalaena australis ), that forages on copepods and krill from ~30°S to the Antarctic ice edge (>60°S)...
March 7, 2023: Proceedings of the National Academy of Sciences of the United States of America
#28
JOURNAL ARTICLE
Yan Zhou, Haowen Zhang, Dazhong Liu, Adel Khashaveh, Qian Li, Kris A G Wyckhuys, Kongming Wu
Insects provide critical ecosystem services such as biological pest control, in which natural enemies (NE) regulate the populations of crop-feeding herbivores (H). While H-NE dynamics are routinely studied at small spatiotemporal scales, multiyear assessments over entire agrolandscapes are rare. Here, we draw on 18-year radar and searchlight trapping datasets (2003-2020) from eastern Asia to (i) assess temporal population trends of 98 airborne insect species and (ii) characterize the associated H-NE interplay...
February 3, 2023: Science Advances
#29
JOURNAL ARTICLE
Arielle Elkrief, Alex Makhnin, Khadeja A Moses, Linda S Ahn, Isabel R Preeshagul, Afsheen N Iqbal, Sara A Hayes, Andrew J Plodkowski, Paul K Paik, Marc Ladanyi, Mark G Kris, Gregory J Riely, Franziska Michor, Helena A Yu
PURPOSE: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance. PATIENTS AND METHODS: We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings...
April 14, 2023: Clinical Cancer Research
#30
JOURNAL ARTICLE
Shidan Wang, Ruichen Rong, Donghan M Yang, Junya Fujimoto, Justin A Bishop, Shirley Yan, Ling Cai, Carmen Behrens, Lynne D Berry, Clare Wilhelm, Dara Aisner, Lynette Sholl, Bruce E Johnson, David J Kwiatkowski, Ignacio I Wistuba, Paul A Bunn, John Minna, Guanghua Xiao, Mark G Kris, Yang Xie
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective for many patients with lung cancer with EGFR mutations. However, not all patients are responsive to EGFR TKIs, including even those harboring EGFR-sensitizing mutations. In this study, we quantified the cells and cellular interaction features of the tumor microenvironment (TME) using routine H&E-stained biopsy sections. These TME features were used to develop a prediction model for survival benefit from EGFR TKI therapy in patients with lung adenocarcinoma and EGFR-sensitizing mutations in the Lung Cancer Mutation Consortium 1 (LCMC1) and validated in an independent LCMC2 cohort...
January 17, 2023: Journal of Clinical Investigation
#31
JOURNAL ARTICLE
Harry B Lengel, Junting Zheng, Kay See Tan, Corinne C Liu, Bernard J Park, Gaetano Rocco, Prasad S Adusumilli, Daniela Molena, Helena A Yu, Gregory J Riely, Manjit S Bains, Valerie W Rusch, Mark G Kris, Jamie E Chaft, Bob T Li, James M Isbell, David R Jones
OBJECTIVE: Targeted therapy improves outcomes in patients with advanced-stage non-small cell lung cancer (NSCLC) and in the adjuvant setting, but data on its use before surgery are limited. We sought to investigate the safety and feasibility of preoperative targeted therapy in patients with operable NSCLC. METHODS: We retrospectively reviewed 51 patients with clinical stage I to III NSCLC who received targeted therapy, alone or in combination with chemotherapy, before surgical resection with curative intent, treated from 2004 to 2021...
November 17, 2022: Journal of Thoracic and Cardiovascular Surgery
#32
JOURNAL ARTICLE
Noura J Choudhury, Antonio Marra, Jane S Y Sui, Jessica Flynn, Soo-Ryum Yang, Christina J Falcon, Pier Selenica, Adam J Schoenfeld, Natasha Rekhtman, Daniel Gomez, Michael F Berger, Marc Ladanyi, Maria Arcila, Charles M Rudin, Gregory J Riely, Mark G Kris, Glenn Heller, Jorge S Reis-Filho, Helena A Yu
INTRODUCTION: Preferred first-line treatment for patients with metastatic EGFR-mutant lung cancer is osimertinib, yet it is not known whether patient outcomes may be improved by identifying and intervening on molecular markers associated with therapeutic resistance. METHODS: All patients with metastatic EGFR-mutant lung cancer treated with first-line osimertinib at the Memorial Sloan Kettering Cancer Center (n = 327) were identified. Available pretreatment and postprogression tumor samples underwent targeted gene panel sequencing and mutational signature analysis using SigMA algorithm...
December 6, 2022: Journal of Thoracic Oncology
#33
JOURNAL ARTICLE
Sandra Díaz, Jens Kattge, Johannes H C Cornelissen, Ian J Wright, Sandra Lavorel, Stéphane Dray, Björn Reu, Michael Kleyer, Christian Wirth, I Colin Prentice, Eric Garnier, Gerhard Bönisch, Mark Westoby, Hendrik Poorter, Peter B Reich, Angela T Moles, John Dickie, Amy E Zanne, Jérôme Chave, S Joseph Wright, Serge N Sheremetiev, Hervé Jactel, Christopher Baraloto, Bruno E L Cerabolini, Simon Pierce, Bill Shipley, Fernando Casanoves, Julia S Joswig, Angela Günther, Valeria Falczuk, Nadja Rüger, Miguel D Mahecha, Lucas D Gorné, Bernard Amiaud, Owen K Atkin, Michael Bahn, Dennis Baldocchi, Michael Beckmann, Benjamin Blonder, William Bond, Ben Bond-Lamberty, Kerry Brown, Sabina Burrascano, Chaeho Byun, Giandiego Campetella, Jeannine Cavender-Bares, F Stuart Chapin, Brendan Choat, David Anthony Coomes, William K Cornwell, Joseph Craine, Dylan Craven, Matteo Dainese, Alessandro Carioca de Araujo, Franciska T de Vries, Tomas Ferreira Domingues, Brian J Enquist, Jaime Fagúndez, Jingyun Fang, Fernando Fernández-Méndez, Maria T Fernandez-Piedade, Henry Ford, Estelle Forey, Gregoire T Freschet, Sophie Gachet, Rachael Gallagher, Walton Green, Greg R Guerin, Alvaro G Gutiérrez, Sandy P Harrison, Wesley Neil Hattingh, Tianhua He, Thomas Hickler, Steven I Higgins, Pedro Higuchi, Jugo Ilic, Robert B Jackson, Adel Jalili, Steven Jansen, Fumito Koike, Christian König, Nathan Kraft, Koen Kramer, Holger Kreft, Ingolf Kühn, Hiroko Kurokawa, Eric G Lamb, Daniel C Laughlin, Michelle Leishman, Simon Lewis, Frédérique Louault, Ana C M Malhado, Peter Manning, Patrick Meir, Maurizio Mencuccini, Julie Messier, Regis Miller, Vanessa Minden, Jane Molofsky, Rebecca Montgomery, Gabriel Montserrat-Martí, Marco Moretti, Sandra Müller, Ülo Niinemets, Romà Ogaya, Kinga Öllerer, Vladimir Onipchenko, Yusuke Onoda, Wim A Ozinga, Juli G Pausas, Begoña Peco, Josep Penuelas, Valério D Pillar, Clara Pladevall, Christine Römermann, Lawren Sack, Norma Salinas, Brody Sandel, Jordi Sardans, Brandon Schamp, Michael Scherer-Lorenzen, Ernst-Detlef Schulze, Fritz Schweingruber, Satomi Shiodera, Ênio Sosinski, Nadejda Soudzilovskaia, Marko J Spasojevic, Emily Swaine, Nathan Swenson, Susanne Tautenhahn, Ken Thompson, Alexia Totte, Rocío Urrutia-Jalabert, Fernando Valladares, Peter van Bodegom, François Vasseur, Kris Verheyen, Denis Vile, Cyrille Violle, Betsy von Holle, Patrick Weigelt, Evan Weiher, Michael C Wiemann, Mathew Williams, Justin Wright, Gerhard Zotz
Here we provide the 'Global Spectrum of Plant Form and Function Dataset', containing species mean values for six vascular plant traits. Together, these traits -plant height, stem specific density, leaf area, leaf mass per area, leaf nitrogen content per dry mass, and diaspore (seed or spore) mass - define the primary axes of variation in plant form and function. The dataset is based on ca. 1 million trait records received via the TRY database (representing ca. 2,500 original publications) and additional unpublished data...
December 7, 2022: Scientific Data
#34
JOURNAL ARTICLE
Valerie W Rusch, Alan Nicholas, G Alexander Patterson, Salama N Waqar, Eric M Toloza, Eric B Haura, Dan J Raz, Karen L Reckamp, Robert E Merritt, Dwight H Owen, David J Finley, Ciaran J McNamee, Justin D Blasberg, Edward B Garon, John D Mitchell, Robert C Doebele, Frank Baciewicz, Misako Nagasaka, Harvey I Pass, Katja Schulze, Ann Johnson, Paul A Bunn, Bruce E Johnson, Mark G Kris, David J Kwiatkowski, Ignacio I Wistuba, Jamie E Chaft, David P Carbone, Jay M Lee
OBJECTIVE: Multimodality treatment for resectable non-small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced non-small cell lung cancer and promising preoperatively in small clinical trials for resectable non-small cell lung cancer. This large multicenter trial tested the safety and efficacy of neoadjuvant atezolizumab and surgery. METHODS: Patients with stage IB to select IIIB resectable non-small cell lung cancer and Eastern Cooperative Oncology Group performance status 0/1 were eligible...
October 8, 2022: Journal of Thoracic and Cardiovascular Surgery
#35
JOURNAL ARTICLE
Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Paul K Paik, Jamie E Chaft, Gowtham Jayakumaran, A Rose Brannon, Ryma Benayed, Ahmet Zehir, Mark Donoghue, Nikolaus Schultz, Debyani Chakravarty, Ritika Kundra, Ramyasree Madupuri, Yonina R Murciano-Goroff, Hai-Yan Tu, Chong-Rui Xu, Andrés Martinez, Clare Wilhelm, Jesse Galle, Bobby Daly, Helena A Yu, Michael Offin, Matthew D Hellmann, Piro Lito, Kathryn C Arbour, Marjorie G Zauderer, Mark G Kris, Kenneth K Ng, Juliana Eng, Isabel Preeshagul, W Victoria Lai, John J Fiore, Afsheen Iqbal, Daniela Molena, Gaetano Rocco, Bernard J Park, Lee P Lim, Mark Li, Candace Tong-Li, Madhawa De Silva, David L Chan, Connie I Diakos, Malinda Itchins, Stephen Clarke, Nick Pavlakis, Adrian Lee, Natasha Rekhtman, Jason Chang, William D Travis, Gregory J Riely, David B Solit, Mithat Gonen, Valerie W Rusch, Andreas Rimner, Daniel Gomez, Alexander Drilon, Howard I Scher, Sohrab P Shah, Michael F Berger, Maria E Arcila, Marc Ladanyi, Ross L Levine, Ronglai Shen, Pedram Razavi, Jorge S Reis-Filho, David R Jones, Charles M Rudin, James M Isbell, Bob T Li
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy. ctDNA detection was associated with shorter survival (hazard ratio (HR), 2.05; 95% confidence interval (CI), 1.74-2.42; P < 0.001) independently of clinicopathologic features and metabolic tumor volume...
November 2022: Nature Medicine
#36
JOURNAL ARTICLE
Katherine He, Raageswari B Nayak, Alexander C Allori, Brian K Brighton, Robert A Cina, Jonathan S Ellison, Michael J Goretsky, Kris R Jatana, Mark R Proctor, Catherine Grant, Vanessa M Thompson, Marie Iwaniuk, Mark E Cohen, Jacqueline M Saito, Bruce L Hall, Jason G Newland, Clifford Y Ko, Shawn J Rangel
Importance: Use of postoperative antimicrobial prophylaxis is common in pediatric surgery despite consensus guidelines recommending discontinuation following incision closure. The association between postoperative prophylaxis use and surgical site infection (SSI) in children undergoing surgical procedures remains poorly characterized. Objective: To evaluate whether use of postoperative surgical prophylaxis is correlated with SSI rates in children undergoing nonemergent surgery...
October 19, 2022: JAMA Surgery
#37
JOURNAL ARTICLE
Paul K Paik, Jia Luo, Ni Ai, Rachel Kim, Linda Ahn, Anup Biswas, Courtney Coker, Wanchao Ma, Phillip Wong, Darren J Buonocore, W Victoria Lai, Jamie E Chaft, Swarnali Acharyya, Joan Massagué, Mark G Kris
We previously identified a chemotherapy-induced paracrine inflammatory loop that paradoxically mitigates the anti-tumor effect of chemotherapy and triggers metastatic propagation in breast and lung cancer models. Therefore, we sought to further validate and translate these findings into patient care by coupling the anti-TNF-α drug certolizumab pegol with standard cisplatin doublet chemotherapy. Here we first validate the anti-metastatic effect of certolizumab in a liver-metastatic Lewis Lung Carcinoma model...
October 15, 2022: Nature Communications
#38
JOURNAL ARTICLE
Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba, David J Kwiatkowski, Dwight H Owen, Yan Tang, Bruce E Johnson, Jay M Lee, Gerard Lozanski, Maciej Pietrzak, Michal Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica Grindheim, Stephanie Hilz, David S Shames, Chris Rivard, Eric Toloza, Eric B Haura, Ciaran J McNamee, G Alexander Patterson, Saiama N Waqar, Valerie W Rusch, David P Carbone
In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 patients with untreated, resectable, stage IB-IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14-28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging...
September 12, 2022: Nature Medicine
#39
RANDOMIZED CONTROLLED TRIAL
Jonathan T Yang, N Ari Wijetunga, Elena Pentsova, Suzanne Wolden, Robert J Young, Denise Correa, Zhigang Zhang, Junting Zheng, Alexa Steckler, Weronika Bucwinska, Ashley Bernstein, Allison Betof Warner, Helena Yu, Mark G Kris, Andrew D Seidman, Jessica A Wilcox, Rachna Malani, Andrew Lin, Lisa M DeAngelis, Nancy Y Lee, Simon N Powell, Adrienne Boire
PURPOSE: Photon involved-field radiotherapy (IFRT) is the standard-of-care radiotherapy for patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton craniospinal irradiation (pCSI) encompassing the entire CNS would result in superior CNS progression-free survival (PFS) compared with IFRT. PATIENTS AND METHODS: We conducted a randomized, phase II trial of pCSI versus IFRT in patients with non-small-cell lung cancer and breast cancers with LM...
November 20, 2022: Journal of Clinical Oncology
#40
RANDOMIZED CONTROLLED TRIAL
Jicheng Lv, Muh Geot Wong, Michelle A Hladunewich, Vivekanand Jha, Lai Seong Hooi, Helen Monaghan, Minghui Zhao, Sean Barbour, Meg J Jardine, Heather N Reich, Daniel Cattran, Richard Glassock, Adeera Levin, David C Wheeler, Mark Woodward, Laurent Billot, Sandrine Stepien, Kris Rogers, Tak Mao Chan, Zhi-Hong Liu, David W Johnson, Alan Cass, John Feehally, Jürgen Floege, Giuseppe Remuzzi, Yangfeng Wu, Rajiv Agarwal, Hong Zhang, Vlado Perkovic
IMPORTANCE: The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. OBJECTIVE: To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function decline. DESIGN, SETTING, AND PARTICIPANTS: An international, multicenter, double-blind, randomized clinical trial that enrolled 503 participants with IgA nephropathy, proteinuria greater than or equal to 1 g per day, and estimated glomerular filtration rate (eGFR) of 20 to 120 mL/min/1...
May 17, 2022: JAMA
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
